18 results about "Riluzole" patented technology

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

Provided for are prodrugs of riluzole and pharmaceutical compositions and methods of use thereof. The prodrugs have advantageous pharmacological properties for use in methods for treating glutamate-associated diseases or disorders, or other diseases or disorders, against which riluzole is known or expected to be effective, including central nervous system (CNS) disorders, neuropsychiatric disorders, and neurodegenerative disorders.

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

The invention belongs to the technical field of chromatography-mass spectrometry detection, and relates to a method for simultaneously detecting concentrations of riluzole and edaravone. The invention establishes an analysis method for simultaneously detecting riluzole and edaravone based on liquid chromatography-tandem mass spectrometry (LC-MS / MS) for the first time. Mass spectrum response signals of the two drugs are remarkably improved by optimizing key conditions such as mass spectrum ion source parameters, collision energy and declustering voltage. Experimental results show that the quantitation limits of riluzole and edaravone in the method provided by the invention are as low as 1 ng / mL, the monitoring requirement under low blood concentration can be met, and the method is particularly suitable for pharmacokinetic research and trace concentration monitoring of patients taking medicine for a long time.

The present invention relates to a process for the preparation of lisethopram. Specifically, the present invention relates to a process for the preparation of 7-(4, 7-diazaspiro [2.5] octane-7-yl)-2-(2, 8-dimethylimidazo [1, 2-b] pyridazin-6-yl) pyrido [1, 2-a] pyrimidin-4-one derivatives, which can be used as pharmaceutically active compounds.

The application discloses a 4-(benzo[d]thiazol-2-yl)benzene-1,2-ethylenediamine compound and a preparation method and application thereof. The structural formula of the compound is: the compound has strong ROS scavenging capacity, inhibits lipid peroxidation, can inhibit ferroptosis caused by an iron death inducer, can reduce brain ischemia and nerve damage caused by brain ischemia, and can relieve symptoms of Parkinson's syndrome and other neurological diseases. Therefore, the ferroptosis inhibitor based on the ferrostain-1 / lirilad structure provided by the application can treat diseases related to ferroptosis through multiple actions and has the potential to be developed into a drug for treating diseases related to ferroptosis. Moreover, the ferroptosis inhibitor can be used as an antioxidant fluorescent probe for high-sensitivity detection of a ferroptosis marker, lipid peroxide (PCOOH / PEOOH), can effectively reverse the ferroptosis process of cells, and has a self-indication capacity. The ferroptosis inhibitor is a solid powder, is convenient to store and use, has a simple synthesis method, high yield, low cost, and good popularization prospect.

The invention discloses a double-drug co-delivery lipidosome and a preparation method and application thereof, and belongs to the technical field of biological medicine and nano-drug delivery, the surface of the double-drug co-delivery lipidosome is modified with Angiopep-2 and COG1410, riluzole is loaded, the Angiopep-2 mediates the lipidosome to cross a blood brain barrier, the COG1410 excites a TREM2 pathway to enhance microglial cell mediated A beta removal, and the riluzole is loaded on the lipidosome. Riluzole inhibits glutamic acid release and promotes removal, so that neuronal hyperactivity is reduced; the preparation method of the liposome comprises the following steps: lipid dissolution, hydration, membrane extrusion and gel column purification. The invention also provides an application of the double-drug co-delivery liposome in medicines for treating Alzheimer's disease, provides a composite nano-drug system with cross-BBB capability, A beta removal and neuroprotection, and overcomes the limitation of the existing therapy.

The invention relates to application of riluzole in preparation of medicines for treating obesity and depression, and particularly discloses application of riluzole or pharmaceutically acceptable salts or derivatives of riluzole, and application of riluzole or pharmaceutically acceptable salts or derivatives of riluzole in preparation of medicines or kits for preventing and / or treating obesity and depression codiseases.

The application relates to the technical field of medicines, and discloses application of a tetra-substituted pyrrole derivative in preparation of a product for treating neurodegenerative diseases. The application provides application of the tetra-substituted pyrrole derivative or a pharmaceutically acceptable salt thereof in preparation of the product for treating neurodegenerative diseases. The tetra-substituted pyrrole derivative has high cell safety, and the neuroprotective effect on glutamic acid damage is far higher than that of atrasentan, edaravone and riluzole which are standard clinical drugs; not only can the tetra-substituted pyrrole derivative effectively correct TDP-43 nuclear and cytoplasmic mislocation, but also has the ability of removing insoluble pathological aggregates which atrasentan does not have; the tetra-substituted pyrrole derivative can more effectively inhibit the co-localization of TDP-43 and stress granule protein G3BP1, and intervene in the formation of pathological granules from the source; on a whole animal model, the tetra-substituted pyrrole derivative successfully converts the advantages at the cell level into significant survival benefits, and significantly prolongs the life span of a disease model fruit fly.

Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.

The invention belongs to the technical field of medicines, and particularly relates to application of Riluzole in preparation of a medicine for treating colon cancer. The invention discloses a drug Riluzole which has very high affinity with GOLGA8B protein, can significantly improve the thermal stability of the GOLGA8B protein and significantly inhibit the growth of colon cancer cells, and the inhibition effect has dose dependence. In addition, the clone formation capability of colon cancer cells can be remarkably inhibited, and the effect of inhibiting the survival of the colon cancer cells is achieved; apoptosis of colon cancer cells can be promoted, and free migration and invasion of the colon cancer cells can be inhibited; the growth of colon cancer tumor (plt; 0.01) can be obviously inhibited, and the tumor volume and the tumor weight are reduced.

The present disclosure relates to a method of treating or ameliorating symptoms of a motor neurone disease and improving motor neuron survival in a subject, more specifically treating or ameliorating symptoms of amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. The treatment method comprises administering a Janus kinase (JAK) inhibitor in combination with one or more compounds selected from a glutamate antagonist and an N-methyl-D-aspartate (NMDA) receptor antagonist, in particular baricitinib in combination with riluzole and / or memantine, and compositions and kits thereof for same.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

The invention relates to a stable litamilast pharmaceutical composition. The present invention relates to a pharmaceutical composition, and specifically discloses a litamilast pharmaceutical composition, which comprises a litamilast bulk drug composition, the litamilast active pharmaceutical ingredient composition comprises litamilast and an impurity A, the content of the impurity A is not higher than 0.05%; the total impurity content of the litamilast active pharmaceutical ingredient composition is not higher than 0.2%. The litamilast pharmaceutical composition provided by the invention can prolong the storage period of the medicine, and can improve the stability problem of the product in the production, storage or clinical use process.

Provided is a method of treating glioblastoma in a patient in need of such treatment, comprising administering to the patient a first dosage form comprising a therapeutically active amount of troriluzole or a pharmaceutically acceptable salt thereof.